Results 141 to 150 of about 2,621,983 (338)
Screening 166 FDA‐approved anticancer drugs identifies the aromatase inhibitor Exemestane as a synergistic partner of PARP inhibitor Olaparib in BRCA‐proficient triple‐negative breast cancer. Exemestane induces ROS‐mediated replication stress, enhancing DNA damage and apoptosis alongside Olaparib.
Nur Aininie Yusoh+5 more
wiley +1 more source
Pericytes change function depending on glioblastoma vicinity: emphasis on immune regulation
Pericytes alter their transcriptome depending on their proximity to the tumor core. In the tumor core, pericytes display a more active state with higher communication strength but with lower immune activation potential and a shift toward extracellular matrix production.
Carolina Buizza+5 more
wiley +1 more source
Gender parity in sports medicine; present imperative not future aspiration. [PDF]
Ormond M, Fitzpatrick D.
europepmc +1 more source
AZD9291 has shown promise in targeted cancer therapy but is limited by resistance. In this study, we employed metabolic labeling and LC–MS/MS to profile time‐resolved nascent protein perturbations, allowing dynamic tracking of drug‐responsive proteins. We demonstrated that increased NNMT expression is associated with drug resistance, highlighting NNMT ...
Zhanwu Hou+5 more
wiley +1 more source
Analysis of the Distribution of Private Research Funding to Sports Medicine Orthopaedic Surgeons. [PDF]
Shah AK+6 more
europepmc +1 more source
Single‐cell transcriptomics of prostate cancer patient‐derived xenografts reveals distinct features of neuroendocrine (NE) subtypes. Tumours with focal NE differentiation (NED) share transcriptional programmes with adenocarcinoma, differing from large and small cell neuroendocrine prostate cancer (NEPC). Our work defines the molecular landscape of NEPC,
Rosalia Quezada Urban+12 more
wiley +1 more source
Rehabilitation and Sports Medicine
Schmidt-Trucksäss A
doaj +1 more source
Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. [PDF]
Vasireddi N+6 more
europepmc +1 more source